Tirzepatide is a dual agonist of GIP and GLP-1 receptors. This dual action improves insulin sensitivity, enhances insulin secretion, and reduces appetite. In clinical studies such as SURMOUNT-1, participants experienced body weight reductions of up to 20.9% over 72 weeks with tirzepatide 15 mg weekly.
Black Pearl Labs supplies tirzepatide in research-grade purity for scientific study only. Not for human consumption.
Black Pearl Labs sells products intended for research and laboratory use only.
Products are not for human or animal consumption and are not approved for diagnostic, therapeutic, or clinical use.
By entering this website, you confirm that: